Heart disease prevention – what place for the glitazones?

January 2006    Volume 13, Issue 1   Br J Cardiol 2006;13:66-70

Authors:
Michael Kirby

This paper considers the role for glitazones in the treatment of type 2 diabetes following publication of the PROactive study, the first major outcome study with this class of agents. The macrovascular benefits of glitazones are discussed. Recent guidance for glitazone prescribing from the Association of British Clinical Diabetologists is also given.

back to top

Comments

There are currently no comments for this article - leave a comment

You must be logged in to post a comment.
Not yet a member? Register now for free.

back to top